Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
Aim: Sphingosine-1-phosphate receptor mediates the egress of lymphocytes from lymphoid organs, and its inhibition results in a decreased number of circulating lymphocytes. The aim of the current study was to investigate the safety and pharmacodynamic and pharmacokinetic characteristics of a novel sp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.930615/full |
| _version_ | 1811340861400678400 |
|---|---|
| author | Inyoung Hwang Sang Won Lee Jaeseong Oh SeungHwan Lee In-Jin Jang Kyung-Sang Yu |
| author_facet | Inyoung Hwang Sang Won Lee Jaeseong Oh SeungHwan Lee In-Jin Jang Kyung-Sang Yu |
| author_sort | Inyoung Hwang |
| collection | DOAJ |
| description | Aim: Sphingosine-1-phosphate receptor mediates the egress of lymphocytes from lymphoid organs, and its inhibition results in a decreased number of circulating lymphocytes. The aim of the current study was to investigate the safety and pharmacodynamic and pharmacokinetic characteristics of a novel sphingosine-1-phosphate receptor modulator, LC51-0255.Methods: A phase 1 randomized, double-blind, placebo-controlled, multiple dosing, dose-escalation study was conducted on healthy Korean male subjects.Results: After single and daily administration of LC51-0255 for 21 days, a dose-dependent decrease in lymphocyte count and heart rate was observed through 0.25–2 mg dose range of LC51-0255. The mean elimination half-life of LC51-0255 was 76–95 h. LC51-0255 was accumulated with a mean accumulation ratio of 5.17–6.64. During the study, LC51-0255 was generally well tolerated. The most common treatment-emergent adverse event was bradycardia. No clinically significant event of arrhythmia, including AV block, was observed. No clinically significant difference in blood pressure was observed between the dose groups. In other safety assessments, no clinically significant abnormalities were observed, except for bradycardia.Conclusion: Daily administration of LC51-0255 in the range of 0.25–2 mg resulted in a dose-dependent reduction of lymphocyte counts and heart rate. LC51-0255 is generally safe and well tolerated in healthy volunteers. |
| first_indexed | 2024-04-13T18:48:18Z |
| format | Article |
| id | doaj.art-79202ba2f9af468080ad9e78f600319e |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T18:48:18Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-79202ba2f9af468080ad9e78f600319e2022-12-22T02:34:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.930615930615Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjectsInyoung Hwang0Sang Won Lee1Jaeseong Oh2SeungHwan Lee3In-Jin Jang4Kyung-Sang Yu5Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Hanyang University Seoul Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South KoreaAim: Sphingosine-1-phosphate receptor mediates the egress of lymphocytes from lymphoid organs, and its inhibition results in a decreased number of circulating lymphocytes. The aim of the current study was to investigate the safety and pharmacodynamic and pharmacokinetic characteristics of a novel sphingosine-1-phosphate receptor modulator, LC51-0255.Methods: A phase 1 randomized, double-blind, placebo-controlled, multiple dosing, dose-escalation study was conducted on healthy Korean male subjects.Results: After single and daily administration of LC51-0255 for 21 days, a dose-dependent decrease in lymphocyte count and heart rate was observed through 0.25–2 mg dose range of LC51-0255. The mean elimination half-life of LC51-0255 was 76–95 h. LC51-0255 was accumulated with a mean accumulation ratio of 5.17–6.64. During the study, LC51-0255 was generally well tolerated. The most common treatment-emergent adverse event was bradycardia. No clinically significant event of arrhythmia, including AV block, was observed. No clinically significant difference in blood pressure was observed between the dose groups. In other safety assessments, no clinically significant abnormalities were observed, except for bradycardia.Conclusion: Daily administration of LC51-0255 in the range of 0.25–2 mg resulted in a dose-dependent reduction of lymphocyte counts and heart rate. LC51-0255 is generally safe and well tolerated in healthy volunteers.https://www.frontiersin.org/articles/10.3389/fphar.2022.930615/fullautoimmune diseaseimmunosuppressionlymphocyte countphase Irandomized controlled trialsphingosine-1-phosphate receptor modulator |
| spellingShingle | Inyoung Hwang Sang Won Lee Jaeseong Oh SeungHwan Lee In-Jin Jang Kyung-Sang Yu Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects Frontiers in Pharmacology autoimmune disease immunosuppression lymphocyte count phase I randomized controlled trial sphingosine-1-phosphate receptor modulator |
| title | Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects |
| title_full | Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects |
| title_fullStr | Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects |
| title_full_unstemmed | Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects |
| title_short | Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects |
| title_sort | dose dependent reduction of lymphocyte count and heart rate after multiple administration of lc51 0255 a novel sphingosine 1 phosphate receptor 1 modulator in healthy subjects |
| topic | autoimmune disease immunosuppression lymphocyte count phase I randomized controlled trial sphingosine-1-phosphate receptor modulator |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.930615/full |
| work_keys_str_mv | AT inyounghwang dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects AT sangwonlee dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects AT jaeseongoh dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects AT seunghwanlee dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects AT injinjang dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects AT kyungsangyu dosedependentreductionoflymphocytecountandheartrateaftermultipleadministrationoflc510255anovelsphingosine1phosphatereceptor1modulatorinhealthysubjects |